Patents by Inventor Mikulas Popovic
Mikulas Popovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9309574Abstract: Disclosed is the molecular cloning of HTLV-III, the adult leukemia and acquired immune deficiency syndrome (AIDS) virus. Clone BH10 contains a 9.0 Kb viral insert constituting the entire HTLV-III genome. Clones BH8 and BH5 contain viral inserts of 5.5 Kb and 3.5 Kb, respectively. These clones are suitable for the development of diagnostic and therapeutic measures for AIDS, as well as use as probes for the detection of AIDS. By scientific convention, HTLV-III, referred to herein also as HIV, has been renamed as HIV-1.Type: GrantFiled: February 8, 1995Date of Patent: April 12, 2016Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Robert C. Gallo, Flossie Wong-Staal, Mikulas Popovic, Beatrice H. Hahn, George M. Shaw, Amanda G. Fisher
-
Patent number: 7232654Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1) to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates tot he DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: September 19, 1994Date of Patent: June 19, 2007Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jean-Claude Chermann, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7217508Abstract: This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: February 22, 1988Date of Patent: May 15, 2007Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Simon Wain-Hobson, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Pierre Tiollais, Marc Alizon, Pierre Sonigo, Stewart Cole, Oliver Danos, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 7205102Abstract: This invention is in the field of lymphadenopathy virus which has been designated Human Immunodeficiency Virus Type 1 (HIV-1). This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.Type: GrantFiled: June 7, 1995Date of Patent: April 17, 2007Assignees: Institut Pasteur, The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Solange Chamaret, Claudine Axler-Blin, Francoise Rey, Marie-Therese Nugeyre, Jacques Gruest, legal representative, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Francois Brun-Vezinet, Jean-Claude Chermann, Francoise Barre-Sinoussi, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan, Jacqueline Gruest, deceased
-
Patent number: 6627395Abstract: The identification, separation, purification, and propagation of the HIV-1 virus is provided. Moreover, the preparation of antigens from HIV-1 is further provided. The identification of HIV-1 involves the purification of a virus sample from lymphocytes and contacting the sample with antibodies, which bind to HIV-1 viruses, is provided. The propagation of HIV-1 virus involves infecting uninfected T lymphocytes with the virus. Moreover, the preparation of antigens from HIV-1 involves the separation of protein components of a purified HIV-1 virus under denaturing conditions.Type: GrantFiled: June 6, 1995Date of Patent: September 30, 2003Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 6600023Abstract: Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. Viral extracts, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients.Type: GrantFiled: February 18, 1993Date of Patent: July 29, 2003Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 6428952Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recongize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS.Type: GrantFiled: April 19, 1995Date of Patent: August 6, 2002Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, G. Sarngadharan
-
Patent number: 6395495Abstract: The invention concerns a retrovirus extract containing a p25 protein which recognizes immunologically sera of patients afflicted with lymphadenopathy syndrom (LAS) or acquired immune deficiency syndrom (AIDS). It relates to a method and kit for in vivo assay of LAS or AIDS involving contacting sera from patients to be diagnosed for such diseases with said retrovirus extract and by detecting the immunological reaction, if any.Type: GrantFiled: November 10, 1999Date of Patent: May 28, 2002Assignees: Institut Pasteur, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Robert C Gallo, Mikulas Popovic, Mangalasseril G Sarngadhar, Claudine Axler-Blin, Solange Chamaret
-
Patent number: 5869313Abstract: The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.Type: GrantFiled: May 14, 1996Date of Patent: February 9, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Marvin S. Reitz, Jr., Genoveffa Franchini, Phillip D. Markham, Robert C. Gallo, Franco C. Lori, Mikulas Popovic, Suzanne Gartner
-
Patent number: 5576000Abstract: The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST 1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.Type: GrantFiled: February 15, 1995Date of Patent: November 19, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Marvin S. Reitz, Jr., Genoveffa Franchini, Phillip D. Markham, Robert C. Gallo, Franco C. Lori, Mikulas Popovic, Suzanne Gartner
-
Patent number: 5420030Abstract: The present invention relates to the HIV-1 strains MN-ST1 and BA-L which are typical United States HIV-1 isotypes. The present invention relates to DNA segments encoding the envelope protein of MN-ST1 or BA-L, to DNA constructs containing such DNA segments and to host cells transformed with such constructs. The viral isolates and envelope proteins of the present invention are of value for use in vaccines and bioassays for the detection of HIV-1 infection in biological samples, such as blood bank samples.Type: GrantFiled: February 25, 1993Date of Patent: May 30, 1995Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Marvin S. Reitz, Jr., Genoveffa Franchini, Phillip D. Markham, Robert C. Gallo, Franco C. Lori, Mikulas Popovic, Suzanne Gartner
-
Patent number: 5254457Abstract: Novel hybridoma cell lines and monoclonal antibodies are provided which can differentiate between HIV-1, HIV-2 and SIV retrovirus isolates. A synthetic peptide which is useful as a universal diagnostic reagent for detecting retroviral infection is also described.Type: GrantFiled: January 11, 1989Date of Patent: October 19, 1993Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Anton A. Minassian, Mikulas Popovic, Robert C. Gallo
-
Patent number: 5135864Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.Type: GrantFiled: November 5, 1987Date of Patent: August 4, 1992Assignees: Institut Pasteur, The United States of America as represented by the Secretary of The Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 4708818Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.Type: GrantFiled: October 8, 1985Date of Patent: November 24, 1987Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human ServicesInventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 4652599Abstract: A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with HTLV-III, which is transformed and provides T-cell populations which are highly susceptible to and permissive for HTLV-III, and convenient for large scale production, isolation, and biological detection of the virus. Other operational neoplastic T-cell lines which are positive for OKT4 marker, e.g., Molt 3, CEM, Ti7.4 and HUT78, can produce HTLV-III in a large amount and retain its unlimited capability for growth.Type: GrantFiled: August 24, 1984Date of Patent: March 24, 1987Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic
-
Patent number: 4647773Abstract: A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with the new variants of HTLV, which are transformed and providing T-cell populations which are highly susceptible and permissive from HTLV-III, and convenience for large scale production, isolation and biological detection of the virus.Type: GrantFiled: April 23, 1984Date of Patent: March 3, 1987Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic
-
Patent number: 4520113Abstract: This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.Type: GrantFiled: April 23, 1984Date of Patent: May 28, 1985Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan